CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) — Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and […]
Intended for U.S. Audience FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation […]